Abstract:An inclusion complex of sulfonamide derived from L-valine (dimethyl 2, 2′- (sulfonylbis (azanediyl)) bis (3-methylbutanoate), (DSBM), with cyclodextrin has been synthesized and characterized using different spectroscopic techniques: FT-IR, 1 H NMR, 13 C NMR, 2D NMR, and UV–Visible. The DFT/B3LYP method was utilized to perform theoretical calculations in order to examine vibrational properties, determine NBO (natural bond orbital) energies, and clarify the frontier molecular orbitals (FMOs). Time-dependent density functional theory TD-DFT calculations were realized for the optimized DSBM and its complex structures. To elucidate the different intermolecular interactions in the complex, a detailed analysis of the topological charge density based on the quantum theory of atoms in molecules (QTAIM) was performed. Moreover, the DHPS from Staphylococcus aureus (PDB code: 1AD4), HIV-1 reverse transcriptase (PDB code: 4KV8), and HIV-1 protease (PDB code: 4Q5M) were selected for molecular docking study. The in silico results indicate that the DSBM and β-CD inclusion complex can be used as a better inhibitor of DHPS enzyme from Staphylococcus aureus bacteria strain. The interaction between DSBM-β-CD inclusion complex and HIV-1 reverse transcriptase (RT) exhibits a higher binding energy (− 147.80 kcal/mol) than that of the drug reference nevirapine (− 103.43 kcal/mol) and DSBM (− 85.53 kcal/mol). The in silico evaluation against HIV-1 protease reveal that the inclusion complex presents antiviral properties better than the free ligand DSBM. Therefore, the in vitro antioxidant activity was evaluated using DPPH radical scavenging. The data show that the cyclodextrin inclusion complex displays an antioxidant activity better than the DSBM and ascorbic acid with inhibition concentration values of 472.71, 427.59, and 513.01 μg/mL for DSBM-β-CD complex, DSBM, and ascorbic acid, respectively. These values reveal that the complexation with β-CD enhances the antioxidant properties. The antimicrobial activity was realized against Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 4157), and Bacillus subtilis (ATCC 9372) bacteria strains; Candida albicans (ATCC 24433) yeast strain; and Aspergillus niger (ATCC 16888) mold strain. The results show that the synthesized compounds are more active against Aspergillus niger with an inhibition zone diameter of 90 mm for both DSBM and its β-CD complex. These results indicate that the formed compounds can act as potent antifungal agents.

Design, In Silico, and In vitro Evaluation of Polymer-Based Drug Conjugates Incorporated with Derivative of Cinnamic Acid, Zidovudine, and 4-Aminosalicylic Acid against Pseudo-HIV-1

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles

Cutting-edge Bioinformatics strategies for synthesizing Cyclotriazadisulfonamide (CADA) analogs in next-Generation HIV therapies

Synthesis of Peptide-Functionalized Poly(bis-sulfone) Copolymers Regulating HIV-1 Entry and Cancer Stem Cell Migration

Design, Synthesis, Biochemical, and Antiviral Evaluations of C6 Benzyl and C6 Biarylmethyl Substituted 2-Hydroxylisoquinoline-1,3-diones: Dual Inhibition against HIV Reverse Transcriptase-Associated RNase H and Polymerase with Antiviral Activities

Design, Synthesis, and Biological Evaluation of Darunavir Analogs as HIV-1 Protease Inhibitors

Synthesis and Biological Evaluation of Novel N-[3-(4-phenylpip-erazin-1-yl)-propyl]-carboxamide Derivatives

Design, synthesis and anti-HIV evaluation of 5-alkyl- 6-(benzo[d][1,3]dioxol-5-alkyl)-2-mercaptopyrimidin-4(3H)-ones as potent HIV-1 NNRTIs

Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir

Medicinal Chemistry Perspectives on the Development of Piperazine-Containing HIV-1 Inhibitors

Molecular design and evaluation of aza-polycyclic carbamoyl pyridones as HIV-1 integrase strand transfer inhibitors

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Anti-HIV potential of diarylpyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors: design, synthesis, docking, TOPKAT analysis and molecular dynamics simulations

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-[1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives

Optimization of the Antiviral Potency and Lipophilicity of Halogenated 2,6‐diarylpyridinamines As a Novel Class of HIV‐1 NNRTIS

In Silico Identification of Novel Aromatic Compounds As Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4

Synthesis, structural characterization, computational studies, and in silico and in vitro biological activities of cyclodextrin inclusion complex with sulfonamide derived from L-valine as antimicrobial and anti-HIV-1 agents

Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators

Molecular Docking Studies of Synthesized Pyridazinone Scaffolds as Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)